Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Stephen A Locarnini"'
Autor:
Sarah R Calabro, Annette E Maczurek, Alison J Morgan, Thomas Tu, Victoria W Wen, Christine Yee, Auvro Mridha, Maggie Lee, William d'Avigdor, Stephen A Locarnini, Geoffrey W McCaughan, Fiona J Warner, Susan V McLennan, Nicholas A Shackel
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e90571 (2014)
The classical paradigm of liver injury asserts that hepatic stellate cells (HSC) produce, remodel and turnover the abnormal extracellular matrix (ECM) of fibrosis via matrix metalloproteinases (MMPs). In extrahepatic tissues MMP production is regulat
Externí odkaz:
https://doaj.org/article/5fb65a4f64194cb481221ea58bfb0859
Publikováno v:
Frontiers in Microbiology, Vol 12 (2021)
Recent interest in the origins and subsequent evolution of the hepatitis B virus (HBV) has strengthened with the discovery of ancient HBV sequences in fossilized remains of humans dating back to the Neolithic period around 7,000 years ago. Metagenomi
Externí odkaz:
https://doaj.org/article/9ad7f37bef784d6d884f8766872b9bc6
Autor:
Samuel A L Hall, Gareth S Burns, Benjamin J Mooney, Rosemary Millen, Rachel Morris, Sara Vogrin, Vijaya Sundararajan, Dilip Ratnam, Miriam T Levy, John S Lubel, Amanda J Nicoll, Simone I Strasser, William Sievert, Paul V Desmond, Meng C Ngu, Peter Angus, Marie Sinclair, Christopher Meredith, Gail Matthews, Peter A Revill, Kathy Jackson, Margaret Littlejohn, Scott Bowden, Stephen A Locarnini, Alexander J Thompson, Kumar Visvanathan
Publikováno v:
The Journal of Infectious Diseases. 227:123-132
Background We evaluated the patterns of peripheral Toll-like receptor (TLR) signaling activity and the expression of TLRs and natural killer (NK) cell activation in a cohort of patients experiencing severe hepatitis flares after stopping nucleot(s)id
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96195df56d6d5554c2616e986f479876
https://doi.org/10.1093/infdis/jiac375
https://doi.org/10.1093/infdis/jiac375
Autor:
Samuel A. L. Hall, Gareth S. Burns, Despina Anagnostou, Sara Vogrin, Vijaya Sundararajan, Dilip Ratnam, Miriam T. Levy, John S. Lubel, Amanda J. Nicoll, Simone I. Strasser, William Sievert, Paul V. Desmond, Meng C. Ngu, Peter Angus, Marie Sinclair, Christopher Meredith, Gail Matthews, Peter A. Revill, Kathy Jackson, Margaret Littlejohn, D. Scott Bowden, Stephen A. Locarnini, Kumar Visvanathan, Alexander J. Thompson
Publikováno v:
Alimentary Pharmacology & Therapeutics. 56:310-320
Current guidelines recommend long-term nucleot(s)ide analogue (NA) therapy for patients with HBeAg-negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss.We performed a prosp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e154ed04ea7a9c079c4e6fce8a8e39a
https://doi.org/10.1111/apt.16968
https://doi.org/10.1111/apt.16968
Autor:
Man‐Fung Yuen, Chi‐Yi Chen, Chun‐Jen Liu, Wen‐Juei Jeng, Magdy Elkhashab, Carla S. Coffin, Won Kim, Susan Greenbloom, Alnoor Ramji, Young S. Lim, Yoon J. Kim, Scott K. Fung, Dong J. Kim, Jeong‐Won Jang, Kwan Sik Lee, Radhakrishnan P. Iyer, Chelsea Macfarlane, Kathy Jackson, Stephen A. Locarnini, Henry L. Y. Chan, Nezam H. Afdhal
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 43(1)
Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c03bf7a1a2cc82ee7ebe287a314dcf7
https://pubmed.ncbi.nlm.nih.gov/36300646
https://pubmed.ncbi.nlm.nih.gov/36300646
Autor:
Samuel Al, Hall, Gareth S, Burns, Benjamin J, Mooney, Rosemary, Millen, Rachel, Morris, Sara, Vogrin, Vijaya, Sundararajan, Dilip, Ratnam, Miriam T, Levy, John S, Lubel, Amanda J, Nicoll, Simone I, Strasser, William, Sievert, Paul V, Desmond, Meng C, Ngu, Peter, Angus, Marie, Sinclair, Christopher, Meredith, Gail, Matthews, Peter A, Revill, Kathy, Jackson, Margaret, Littlejohn, Scott, Bowden, Stephen A, Locarnini, Alexander J, Thompson, Kumar, Visvanathan
Publikováno v:
The Journal of infectious diseases.
We evaluated the patterns of peripheral TLR signalling activity and the expression of TLRs and NK cell activation in a cohort of patients experiencing severe hepatitis flares after stopping NA therapy.Samples were collected longitudinally from CHB pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a9c56919424bb7e9407387e6021a9a38
https://pubmed.ncbi.nlm.nih.gov/36108079
https://pubmed.ncbi.nlm.nih.gov/36108079
Autor:
Gail V Matthews, Rachel J Ali, Anchalee Avihingsanon, Janaki Amin, Rachel Hammond, Scott Bowden, Sharon R Lewin, Joe Sasadeusz, Margaret Littlejohn, Stephen L Locarnini, Kiat Ruxrungtham, Gregory J Dore
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61297 (2013)
OBJECTIVE: Anti-HBe seroconversion and HBsAg loss are important therapeutic endpoints in patients with hepatitis B virus (HBV) infection. Quantitative measures of hepatitis B surface antigen (qHBsAg) and e antigen (qHBeAg) have been identified as pot
Externí odkaz:
https://doaj.org/article/07720dc4ef7a4d079f646f7eead862aa
Autor:
Stephen A. Locarnini, Darren J. Wong
Publikováno v:
Hepatitis B Virus and Liver Disease ISBN: 9789811048425
The hepatitis B virus is a prevalent human infection with no cure at present. It is a significant cause of global morbidity and mortality and has achieved its persistence in humans via its complex life cycle and ability to use its few protein product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::129db2b85c12b9a4ba64296ccd837bcd
https://doi.org/10.1007/978-981-10-4843-2_1
https://doi.org/10.1007/978-981-10-4843-2_1
Autor:
Thomas, Schluep, Jason, Lickliter, James, Hamilton, David L, Lewis, Ching-Lung, Lai, Johnson Yn, Lau, Stephen A, Locarnini, Robert G, Gish, Bruce D, Given
Publikováno v:
Clinical Pharmacology in Drug Development
ARC‐520 Injection, an RNA interference drug for the treatment of hepatitis B that targets cccDNA‐derived viral mRNA transcripts with high specificity, effectively reduces the production of viral proteins and HBV DNA. In this phase 1 randomized, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6ef7c9602ccef9c72dc0493274bf3ac9
https://pubmed.ncbi.nlm.nih.gov/27739230
https://pubmed.ncbi.nlm.nih.gov/27739230
Publikováno v:
Clinical Virology. :673-707
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fcc28b24c2a4827978e4d3f1d0e9a02
https://doi.org/10.1128/9781555815981.ch31
https://doi.org/10.1128/9781555815981.ch31